Therapeutic potential of various β-glucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy

Cancer Biology and Therapy

Volumn 8, Issue 3, 2009, Pages 218-225

  Driscoll, Michael ^a   Hansen, Richard ^a   Ding, Chuanlin ^a   Cramer, Daniel E ^a   Yan, Jun ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Anti tumor monoclonal antibody; Cytokine; Immunotherapy; Toll like receptor; glucan

Indexed keywords

B7 ANTIGEN; BETA GLUCAN; CANCER ANTIBODY; CD40 ANTIGEN; CD86 ANTIGEN; COMPLEMENT COMPONENT C3 RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; MUCIN 1 ANTIBODY; MYELOID DIFFERENTIATION FACTOR 88; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY MUC 1; MONOCLONAL ANTIBODY MUC-1;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CARCINOMA CELL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOMA; MACROPHAGE; MALE; MONOTHERAPY; MOUSE; MUSHROOM; NONHUMAN; OVARY CARCINOMA; TREATMENT DURATION; UPREGULATION; YEAST; ANIMAL; BIOSYNTHESIS; CELL LINE; CHEMISTRY; COMPARATIVE STUDY; CULTURE TECHNIQUE; DIET SUPPLEMENTATION; DRUG EFFECT; EXPERIMENTAL NEOPLASM; GANODERMA LUCIDUM; GRIFOLA; IMMUNOLOGY; LENTINULA EDODES; METABOLISM; SACCHAROMYCES CEREVISIAE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; BETA-GLUCANS; CELL CULTURE TECHNIQUES; CELL LINE; DENDRITIC CELLS; DIETARY SUPPLEMENTS; GRIFOLA; HUMANS; INTERLEUKIN-12; MACROPHAGES; MALE; MICE; NEOPLASMS, EXPERIMENTAL; REISHI; SACCHAROMYCES CEREVISIAE; SHIITAKE MUSHROOMS; TREATMENT OUTCOME;

EID: 61449128426     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.3.7337     Document Type: Article

References (42)

1. Diller IC, Mankowski ZT, Fisher ME. The effect of yeast polysaccharides on mouse tumors. Cancer Res 1963; 23:201-8.
2. Wasser SP, Weis AL. Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: A modern perspective. Crit Rev Immunol 1999; 19:65-96.
3. Gawronski M, Park JT, Magee AS, Conrad H. Microfibrillar structure of PGG-glucan in aqueous solution as triple-helix aggregates by small angle x-ray scattering. Biopolymers 1999; 50:569-78.
4. Yan J, Allendorf DJ, Brandley B. Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer. Expert Opin Biol Ther 2005; 5:691-702.
5. Borchers AT, Keen CL, Gershwin ME. Mushrooms, tumors and immunity: An update. Exp Biol Med (Maywood) 2004; 229:393-406.
6. Williams DL, Pretus HA, McNamee RB, Jones EL, Ensley HE, Browder IW, et al. Development, physicochemical characterization and preclinical efficacy evaluation of a water soluble glucan sulfate derived from Saccharomyces cerevisiae. Immunopharmacology 1991; 22:139-55.
7. Babineau TJ, Hackford A, Kenler A, Bistrian B, Forse RA, Fairchild PG, et al. A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch Surg 1994; 129:1204-10.
8. Babineau TJ, Marcello P, Swails W, Kenler A, Bistrian B, Forse RA. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann Surg 1994; 220:601-9.
9. Tzianabos AO, Cisneros RL. Prophylaxis with the immunomodulator PGG glucan enhances antibiotic efficacy in rats infected with antibiotic-resistant bacteria. Ann N Y Acad Sci 1996; 797:285-7.
10. Liang J, Melican D, Cafro L, Palace G, Fisette L, Armstrong R, et al. Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. Int J Immunopharmacol 1998; 20:595-614.
11. Patchen ML, Vaudrain T, Correira H, Martin T, Reese D. In vitro and in vivo hematopoietic activities of Betafectin PGG-glucan. Exp Hematol 1998; 26:1247-54.
12. Reichner JS, Fitzpatrick PA, Wakshull E, Albina JE. Receptor-mediated phagocytosis of rat macrophages is regulated differentially for opsonized particles and non-opsonized particles containing beta-glucan. Immunology 2001; 104:198-206.
13. Vetvicka V, Thornton BP, Ross GD. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Invest 1996; 98:50-61.
14. Thornton BP, Vetvicka V, Pitman M, Goldman RC, Ross GD. Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol 1996; 156:1235-46.
15. Xia Y, Vetvicka V, Yan J, Hanikyrova M, Mayadas T, Ross GD. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J Immunol 1999; 162:2281-90.
16. Yan J, Vetvicka V, Xia Y, Coxon A, Carroll MC, Mayadas TN, et al. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J Immunol 1999; 163:3045-52.
17. Hong F, Hansen RD, Yan J, Allendorf DJ, Baran JT, Ostroff GR, et al. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res 2003; 63:9023-31.
18. Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, et al. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol 2004; 173:797-806.
19. Li B, Allendorf DJ, Hansen R, Marroquin J, Ding C, Cramer DE, et al. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J Immunol 2006; 177:1661-9.
20. Allendorf DJ, Yan J, Ross GD, Hansen RD, Baran JT, Subbarao K, et al. C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and {beta}-glucan. J Immunol 2005; 174:7050-6.
21. Li B, Cramer D, Wagner S, Hansen R, King C, Kakar S, et al. Yeast glucan particles activate murine resident macrophages to secrete proinflammatory cytokines via MyD88- and Syk kinase-dependent pathways. Clin Immunol 2007; 124:170-81.
22. Gilliet M, Boonstra A, Paturel C, Antonenko S, Xu XL, Trinchieri G, et al. The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor. J Exp Med 2002; 195:953-8.
23. Brawand P, Fitzpatrick DR, Greenfield BW, Brasel K, Maliszewski CR, De Smedt T. Murine plasmacytoid pre-dendritic cells generated from Flt3 ligand-supplemented bone marrow cultures are immature APCs. J Immunol 2002; 169:6711-9.
24. Cuesta G, Suarez N, Bessio MI, Ferreira F, Massaldi H. Quantitative determination of pneumococcal capsular polysaccharide serotype 14 using a modification of phenol-sulfuric acid method. J Microbiol Methods 2003; 52:69-73.
25. Li B, Allendorf DJ, Hansen R, Marroquin J, Cramer DE, Harris CL, et al. Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55. Cancer Res 2007; 67:7421-30.
26. Brown GD, Herre J, Williams DL, Willment JA, Marshall AS, Gordon S. Dectin-1 mediates the biological effects of beta-glucans. J Exp Med 2003; 197:1119-24.
27. Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM. Collaborative induction of inflammatory responses by dectin-1 and toll-like receptor 2. J Exp Med 2003; 197:1107-17.
28. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499-511.
29. Brunda MJ. Interleukin-12. J Leukoc Biol 1994; 55:280-8.
30. Gately MK, Gubler U, Brunda MJ, Nadeau RR, Anderson TD, Lipman JM, et al. Interleukin-12: A cytokine with therapeutic potential in oncology and infectious diseases. Ther Immunol 1994; 1:187-96.
31. Nisini R, Torosantucci A, Romagnoli G, Chiani P, Donati S, Gagliardi MC, et al. {beta}-Glucan of Candida albicans cell wall causes the subversion of human monocyte differentiation into dendritic cells. J Leukoc Biol 2007.
32. Ross GD. Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein. Crit Rev Immunol 2000; 20:197-222.
33. Zimmerman JW, Lindermuth J, Fish PA, Palace GP, Stevenson TT, DeMong DE. A novel carbohydrate-glycosphingolipid interaction between a beta-(1-3)-glucan immuno-modulator, PGG-glucan and lactosylceramide of human leukocytes. J Biol Chem 1998; 273:22014-20.
34. Rice PJ, Kelley JL, Kogan G, Ensley HE, Kalbfleisch JH, Browder IW, et al. Human monocyte scavenger receptors are pattern recognition receptors for (1→3)-beta-D-glucans. J Leukoc Biol 2002; 72:140-6.
35. Brown GD, Gordon S. Immune recognition. A new receptor for beta-glucans. Nature 2001; 413:36-7.
36. Rogers NC, Slack EC, Edwards AD, Nolte MA, Schulz O, Schweighoffer E, et al. Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity 2005; 22:507-17.
37. Saijo S, Fujikado N, Furuta T, Chung SH, Kotaki H, Seki K, et al. Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat Immunol 2007; 8:39-46.
38. Zhang X, Kimura Y, Fang C, Zhou L, Sfyroera G, Lambris JD, et al. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood 2007; 110:228-36.
39. Ehirchiou D, Xiong Y, Xu G, Chen W, Shi Y, Zhang L. CD11b facilitates the development of peripheral tolerance by suppressing Th17 differentiation. J Exp Med 2007; 204:1519-24.
40. Hammerberg C, Katiyar SK, Carroll MC, Cooper KD. Activated complement component 3 (C3) is required for ultraviolet induction of immunosuppression and antigenic tolerance. J Exp Med 1998; 187:1133-8.
41. Sohn JH, Bora PS, Suk HJ, Molina H, Kaplan HJ, Bora NS. Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells. Nat Med 2003; 9:206-12.
42. Gao Y, Zhang D, Sun B, Fujii H, Kosuna K, Yin Z. Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses. Cancer Immunol Immunother 2006; 55:1258-66.